REGULATORY

Japan Generic Share at 79% in September 2021: Drug Price Survey

December 6, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The volume-based generic utilization rate in Japan stood at “approximately 79.0%” in September 2021, according to the results of a drug price survey released on December 3.The rate was up by 0.7 point from 78.3% yielded in the previous survey…

To read the full story

Average NHI-Market Price Gap of Listed Drugs at 7.6%: MHLW
December 3, 2021

REGULATORY

US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…